Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper Rash Prophylaxis
Launched by TRIMA, ISRAEL PHARMACEUTICAL PRODUCTS · Jul 21, 2010
Trial Information
Current as of May 19, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy male or female infants aged between 3-18 months who are routine users of disposable diapers
- Exclusion Criteria:
- • Children with symptoms of systemic disease or skin lesions.
- • Children diagnosed as having diaper dermatitis at baseline
- • Known hypersensitivity to any of the components of the trial preparations.
- • Children suffering from atopic diseases.
- • Children who have participated during the last month in another clinical trial.
About Trima, Israel Pharmaceutical Products
Trima, based in Israel, is a leading pharmaceutical company dedicated to the development and commercialization of innovative therapeutic solutions. With a strong focus on clinical research and a commitment to advancing healthcare, Trima specializes in a diverse array of pharmaceutical products that address unmet medical needs. The company leverages cutting-edge technology and rigorous scientific methodologies to ensure the efficacy and safety of its offerings. Trima is committed to enhancing patient outcomes through extensive collaboration with healthcare professionals and regulatory bodies, positioning itself as a key player in the global pharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Kobi Shiff, MD
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials